Introduction
Chronic heart failure (CHF) is a life-threatening condition affecting approximately 26 million people worldwide, and heart failure carries substantial risk of morbidity and mortality. 1 Recent advances in non-pharmacological treatment, including device therapy, can improve quality of life and survival in CHF patients. Ineffective or less appropriate use of aggressive therapeutic approaches, however, has been reported not only in high-risk patients with advanced systolic dysfunction or end-stage heart failure but also those at a low risk for 2 From a medico-economical point of view, there is a clear need for more precise risk-stratification in order to achieve more effective management of CHF. With respect to risk assessment for cardiac mortality, conventional functional evaluations, and diagnostic biomarkers, such as heart failure symptoms, circulating hormones and peptides, and left ventricular functional parameters, have non-negligible limitations in the discrimination of low-, intermediate-, and high-risk as a basis for short-or long-term clinical management. To enhance the utility of individual risk markers, a large number of multivariate risk models have been developed in the past 2 decades. [3] [4] [5] However, use of these models in clinical practice remains limited. 6, 7 Sympathetic nerve function plays a crucial role in CHF outcomes. In the early stages of CHF, sympathetic nerve function is increased to compensate for symptomatic and cardiac functional deteriorations. With a CHF progression, however, sympathetic outflow and circulating neurohormones become further augmented and long-lasting sympathetic hyperactivity induces a loss of both presynaptic neurons and post-synaptic receptors, 8, 9 resulting in compensatory mechanisms being blunted and in unfavourable outcomes. In the clinical assessment of CHF condition, neuroimaging with 123 I-meta-iodobenzylguanidine (MIBG) is a unique diagnostic method to evaluate the integrity of cardiac sympathetic activity and innervation. 9 Furthermore, a number of studies have demonstrated the potent prognostic values of cardiac 123 I-MIBG activity, [10] [11] [12] [13] [14] [15] which is quantified as a heart-tomediastinum ratio (HMR), in a single-and multi-centre studies. [16] [17] [18] [19] Recently, a CHF mortality risk model using a cardiac 123 I-MIBG parameter together with clinical information was developed using a Japanese CHF database consisting of 1322 patients, which was shown effective for the prediction of 2-and 5-year cardiac mortality risks. 20, 21 The present study was designed to validate the predictability of the 2-year mortality risk model using a new cohort of CHF patients derived from multiple clinical centres in Japan.
Methods Patients
A total of 546 patients diagnosed with CHF who had undergone 123 I-MIBG study during clinically stable condition, and had been followed up for at least 1 year in four medical centres were retrospectively included in this study ( Table 1) . Cardiac 123 I-MIBG studies were performed between 2005 and 2016. An average follow-up period was 30 ± 20 months (range 0.1-108 months) and left ventricular ejection fraction (LVEF) either by echocardiography or gated single-photon emission computed tomography was 39 ± 14%. New York Heart Association (NYHA) functional class was 77% in class I/II and 23% in III/IV. CHF aetiology was ischemic in 36% of the patients. Standard optimal medical care for CHF was continued in each university and community hospital after MIBG imaging. Seventy-three (13%) patients underwent haemodialysis due to chronic renal failure.
Cardiac

I-MIBG imaging
Planar anterior images of the thorax were obtained at 15-20 min (early) and 3-4 h (late) after intravenous injection of 123 I-MIBG (111 MBq, FUJIFILM RI Pharma Co. Ltd., Tokyo, Japan). Image processing was performed locally at each institution. Regions of interest were set over the heart and upper mediastinum to calculate an HMR. Since collimators used in the four hospitals were low-energy (LE) high-resolution, LE general purpose, and low-medium energy general-purpose collimators, all the HMR values were converted to medium-energy (ME) generalpurpose collimator-equivalent HMR [conversion coefficient (CC) of 0.88 by phantom experiments] by using the standardization method developed previously. 22 
Definitions of events
A primary endpoint in this study was cardiac death; end-stage heart failure death (death due to pump failure), arrhythmic/sudden cardiac death and fatal acute myocardial infarction. The following non-fatal arrhythmic events were also documented; appropriate anti-arrhythmia pacing against lethal arrhythmias, and appropriate discharge by implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy with defibrillator (CRTD).
2-year mortality risk model
The 2-year risk model was developed based on a database consisting of 1280 subjects who underwent MIBG imaging from 1990 to 2009 in Japan. 21 In that study, the multivariate logistic model selected four significant independent variables: age, LVEF, NYHA functional class (I-II vs. III-IV), and MIBG HMR. The risk model provides a 2-year probability of cardiac death (unit %/2 years) due to pump failure, sudden cardiac death, lethal arrhythmia, and/or acute myocardial infarction.
Statistical analysis
All the values were expressed as mean ± standard deviations (SDs). Mean values among groups were compared using analysis of variance with T-and F-tests and comparison of all pairs by Tukey-Kramer (honestly significant difference) statistics. Kaplan-Meier survival analysis was performed among three groups classified by thresholds of LVEF, a predicted 2-year mortality risk and BNP/NT-ProBNP as follows. LVEF groups were <35%, 35-50%, and >50%: 2-year mortality risk groups were <4%, 4-12%, and >12%: BNP and NT-ProBNP groups were <100, 100-200, >200 pg/mL, and <400, 400-900, and >900 pg/mL, respectively. 24, 25 Predicted mortality by the risk model was compared with actual outcomes observed during the follow-up period in patients in whom 2-year follow-up data were available. Receiveroperating characteristics (ROCs) analysis with area under curve (AUC) was used to compare the risk model and individual variables. A P-value <0.05 was considered significant. All analyses were performed using the SAS statistical program package (JMP version 12, SAS, Cary, NC, USA).
Results
Number of events
Fatal events occurred in 137 (25%) patients; 105 (68%) patients due to pump failure and the remaining 32 patients due to arrhythmic or sudden death. Non-fatal arrhythmic events were observed in 17 patients; resuscitated cardiac arrest in 5 and appropriate ICD shocks in 12 (29%) of 41 patients undergoing ICD/CRTD therapy. The total number of events was 154 (28%).
Survival analysis
The actually documented 2-year mortality rates of 3 predicted risk groups (<4%, 4-12%, and >12%) were 1.6, 8.4, and 48.5% (P < 0.0001), respectively ( Figure 1 ). For further comparisons of survival curves, thresholds of LVEF and BNP/NT-ProBNP were combined with the predicted 2-year mortality risks. The survival rates in the three LVEF subgroups (<30%, 30-35%, and >35%) were significantly discriminated by the risk model (P < 0.0001 for all) ( Figure 2) . Likewise, the survival rates in the three BNP/NT-ProBNP subgroups were significantly (P = 0.003 to P < 0.0001) discriminated ( Figure 3 ).
Comparison of predicted and actual mortality
The average 2-year mortality rate predicted by the risk model was 12.1 ± 10.9% (range 0.0-52.1%, median 8.3%). Based upon predicted risks, patients were classified into quartiles; <5.1% for Q1, 5.1-8.2% for Q2, 8.3-13.7% for Q3, and > _13.8% for Q4. With respect to clinical backgrounds, Q3 and Q4 groups showed greater abnormalities of MIBG HMR, BNP/NT-ProBNP levels, estimated glomerular filtration rate (eGFR), and LVEF than did Q1 and Q2 groups ( Table 2) . The 2-year mortality rates predicted by the risk model were nearly identical to those actually documented in Q1-Q3; 3% vs. 4% for Q1; 7% vs. 8% for Q2; and 11% vs. 15% for Q3, respectively. The risk model, underestimated the mortality rate in Q4: 28% vs. 54% (Figure 4 ).
Prediction of heart failure death
Because most frequent deaths observed in the study were due to progressive heart failure, the predictability of this event was compared among the 2-year risk model, MIBG HMR, BNP/NT-ProBNP, eGFR, and LVEF by ROC analysis ( Figure 5 ). For this analysis, additional thresholds of natriuretic peptide levels were determined by ROC analysis as follows; 560 pg/mL for BNP and 4800 pg/mL for NTProBNP. The 2-year risk model had the significantly greater (v 2 = 58, 
Arrhythmic death and appropriate cardiac device therapy
When arrhythmic/sudden cardiac death and non-fatal arrhythmic events with appropriate treatment of ICD and CRTD (n = 26) were combined, the observed event rates were 3.7%, 2.9%, 4.4%, and 8.1% for Q1, Q2, Q3, and Q4, respectively (P = 0.0359 for trend). However, when HMR quartiles of < 1.43 (n = 137), 1.43-1.66 (n = 132), 1.67-1.92 (n = 141), and >1.92 (n = 136) were analysed, the observed event rates were 5.1%, 8.3%, 3.6%, and 2.2%, respectively (P = 0.10).
Discussion
The presented findings validated the reliability of the 2-year risk model developed by combining cardiac 123 I-MIBG HMR with clinical information. The prediction of the 2-year risk model was superior to that of individual variables such as LVEF, BNP/NT-ProBNP, or MIBG HMR. It is particularly noted that, irrespective of LVEF and BNP/NTproBNP levels, the risk model discriminated CHF patients at low to intermediate risks. The high-risk population was well discriminated from others, but the actual event rate observed was underestimated by this model. I-MIBG HMR is a powerful measurement for predicting progression and fatal outcomes of CHF, including lethal arrhythmias and sudden cardiac death. [16] [17] [18] [19] The present findings further support the clinical utilities of a 2-year risk model for predicting the probability of lethal cardiac events. BNP and NT-ProBNP are routinely used at a clinical practice as biomarkers for initial diagnosis and for monitoring therapeutic effects in CHF. During a relatively long-term entry interval, both BNP and NT-ProBNP data were collected for this study. BNP and NT-ProBNP have different physiological properties, and are affected by age and renal function. Because of a difficulty in a simple conversion, these parameters were treated as categorical variables for statistical analysis based on the recommendations of Japanese Heart Failure Society and European Society of Cardiology. 24, 25 Irrespective of LVEF and BNP/NT-ProBNP categories, a high-risk population with a 2-year cardiac mortality risk more than 12% was clearly identified and discriminated from other populations at lowto-intermediate risks.
Utility of 123 I-MIBG and classical prognostic biomarkers
Accuracy for prediction of cardiac death
The 2-year risk model demonstrated satisfactory diagnostic accuracy in low-to intermediate-risk patients who had 2-year mortality risk less than 14%. In high-risk patients who were predicted to have a mortality risk of more than 14%, however, the actual cardiac death rate was nearly two times greater than predicted. There are several I-MIBG imaging in CHF. [12] [13] [14] 29, 30 As these studies tended to include larger proportions of patients with less severe CHF being closely followed, it is likely the derivation population experienced fewer adverse outcomes compared with an unselected cohort of clinical HF patients. This is borne out by the overall relatively low 2-year cardiac death rate in the total derivation population (9.8%) as well as in NYHA classes III and IV patients (18% and 30%, respectively). The greater disease severity in Figure 3 Survival analysis of three 2-year risk groups (<4%, 4-12%, and >12%) for three BNP/NT-ProBNP ranges of BNP <100 pg/mL or NTProBNP <400 pg/mL (A), BNP 100-200 pg/mL or NT-ProBNP 400-900 pg/mL (B), and BNP >200 pg/mL or NT-ProBNP >900 pg/mL (C). BNP, b-type natriuretic peptide; eGFR, estimated glomerular filtration rate; HMR, heart-to-mediastinum ration; LE, low energy; LVEF, left ventricular ejection fraction; ME, medium energy; MIBG, meta-iodobenzylguanidine; NT-ProBNP, N-terminal Pro-BNP. the validation population is also observed in eGFR results [65 ± 23 and 50 ±29 mL/min/1.73 m 2 for the derivation (n = 324 available) and validation datasets, respectively; P < 0.0001] and BNP levels [mean BNP 373 (range 5-2996) pg/mL and 475 (range 3-4370) pg/mL, respectively; P = 0.019]. The lower eGFR results in the present study reflected inclusion of many high-risk patients with chronic renal dysfunction and haemodialysis. 31, 32 Given the known adverse prognostic significance of high BNP/NTProBNP and low eGFR in CHF patients, absence of these variables in the risk model is probably the primary reason why the predicted mortality rate was underestimated in the highest risk patients in the validation cohort. Such high-risk patients were more likely to undergo 123 I-MIBG imaging in Japan in the 2000s since clinical use of the technique expanded to patients with more severe CHF and those with comorbidities such as diabetes and renal failure. An additional supplementary model including BNP/NT-ProBNP and eGFR may improve the predictive accuracy for identifying exceptionally highrisk patients.
Discrimination of low-to intermediateand high-risk patients
Irrespective of LVEF and BNP/NT-ProBNP levels, a low risk prediction by the model was validated; no patients died when the 2-year mortality risk was <2% and the observed cardiac mortality was 1.6% when the predicted risk was <4%. Likewise, a high-risk population with a 2-year cardiac mortality risk more than 12% was clearly discriminated from the populations at low-to intermediate-risks. Thus, the presented risk-stratification concept incorporating cardiac sympathetic functional parameters can address some limitations of conventional prognostic biomarkers recommended by the current guidelines 6, 7 and help select more appropriate therapeutic strategies.
For example, patients with LVEF > _35% but at a high risk in this model (i.e. a 2-year cardiac mortality risk >12%) could benefit from more aggressive medical and device treatments. On the other hand, patients who have LVEF <35% but are at a low risk in this model (i.e. 2-year cardiac mortality risk <4%) may be able to undergo less aggressive treatment than that recommended by current guidelines.
Prediction of heart failure death and lethal arrhythmic events
With respect to pump-failure death, the 2-year risk model had definitively better predictive capability compared with each conventional variable such as LVEF, BNP/NT-ProBNP, renal function, and HMR. Concerning arrhythmia/sudden death events including appropriate ICD/CRTD shocks, however, the presented results are more [35] [36] [37] probably because impaired cardiac sympathetic innervation and residual myocardial viability is synergistically related to arrhythmogenic substrate, inhomogeneous refractory period, and denervated supersensitivity to adrenoceptor function of myocytes.
38,39
Standardized HMR for the risk model
As HMR calculated in ME-and LE-collimator conditions differed significantly ( Table 1) , importance of adjusting HMR among institutions was recognized. The CC of 0.60 was used for internal calculation even after standardization to the ME collimator condition (CC of 0.88). 21, 22 The use of HMR standardization enabled inter-institutional comparison and allowed inclusion of more patients for this validation study than would have been available if only images acquired using LE collimation (as per the derivation study) were accepted. The linear HMR conversion enhanced the current validation study by increasing the sample size and the robustness of the statistical analyses.
Limitations
Because of a retrospective and non-interventional nature, patients were studied over a long-term interval (2005-16). The 2-year risk model was developed by the database of patient data collected between 1990 and 2009 during which cardiac device treatment was not widely available at cardiac practice. In this context, advances in therapeutic strategies and revised guidelines for CHF might have affected outcomes and current cardiac prognosis of CHF patients modifiable by recent devices and pharmacotherapy. Such modifications by the treatments cannot be necessarily predicted precisely by the presented risk model. Nevertheless, the good agreement between the predicted risk and the observed outcomes in this study using the relatively recent cohort indicates that the limitation is less important particularly in patients at a low-to intermediate-mortality risk. For example, improved therapeutics would be less likely to have a dramatic effect on prognosis in a derivation cohort patient with low-risk characteristics than in one with a high-risk profile, an expectation consistent with the results shown in this validation study. On the other hand, patients at high-risk despite use of modern therapeutics such as implanted devices could be the subset that resulted in underestimation of risk by the model. A further study in patients eligible for and receiving devices is required to more appropriately identify high-risk patients who could benefit most from current indications of ICD/CRT/CRTD.
Conclusion
The 2-year risk model with age, NYHA functional class, MIBG HMR, and LVEF was successfully validated by the good agreement between predicted and observed cardiac mortality rates and by showing the better predictive accuracy of heart failure death compared with LVEF, BNP/NT-Pro BNP, or HMR alone. The prognostic value is evident particularly when CHF patients at a low to intermediate cardiac mortality risk.
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